Silva Pharmaceuticals Limited (DSE: SILVAPHL)
Bangladesh
· Delayed Price · Currency is BDT 10.40
-0.10 (-0.95%)
At close: Dec 19, 2024
Silva Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2016 |
| Revenue | 547.07 | 599.66 | 716.87 | 778.67 | 799.25 | 763.34 | Upgrade
|
| Revenue Growth (YoY) | -18.46% | -16.35% | -7.94% | -2.57% | 4.70% | 4.22% | Upgrade
|
| Cost of Revenue | 404.27 | 439.35 | 487.58 | 492.89 | 486.26 | 465.91 | Upgrade
|
| Gross Profit | 142.8 | 160.31 | 229.29 | 285.78 | 312.99 | 297.42 | Upgrade
|
| Selling, General & Admin | 216.67 | 208.55 | 185.61 | 175.07 | 171.85 | 158.03 | Upgrade
|
| Other Operating Expenses | -1.05 | -1.05 | -1.1 | -1.05 | -0.94 | -0.93 | Upgrade
|
| Operating Expenses | 215.62 | 207.51 | 184.51 | 174.02 | 170.91 | 157.1 | Upgrade
|
| Operating Income | -72.83 | -47.2 | 44.78 | 111.76 | 142.09 | 140.32 | Upgrade
|
| Interest Expense | -4.86 | -4.38 | -3.61 | -4.71 | -2.78 | -1.46 | Upgrade
|
| Interest & Investment Income | 5.99 | 5.17 | 9.45 | 9.67 | 12.05 | 20.22 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.17 | -0.08 | -0.26 | -0.05 | -0.02 | - | Upgrade
|
| Pretax Income | -71.87 | -46.5 | 50.36 | 116.67 | 151.35 | 159.09 | Upgrade
|
| Income Tax Expense | 17.9 | 17.99 | 17.29 | 14.41 | 31.49 | 40.14 | Upgrade
|
| Net Income | -89.76 | -64.48 | 33.08 | 102.26 | 119.85 | 118.94 | Upgrade
|
| Net Income to Common | -89.76 | -64.48 | 33.08 | 102.26 | 119.85 | 118.94 | Upgrade
|
| Net Income Growth | - | - | -67.65% | -14.68% | 0.77% | -17.01% | Upgrade
|
| Shares Outstanding (Basic) | 137 | 137 | 137 | 137 | 137 | 137 | Upgrade
|
| Shares Outstanding (Diluted) | 137 | 137 | 137 | 137 | 137 | 137 | Upgrade
|
| EPS (Basic) | -0.66 | -0.47 | 0.24 | 0.75 | 0.88 | 0.87 | Upgrade
|
| EPS (Diluted) | -0.66 | -0.47 | 0.24 | 0.75 | 0.88 | 0.87 | Upgrade
|
| EPS Growth | - | - | -67.65% | -14.68% | 0.93% | -17.14% | Upgrade
|
| Free Cash Flow | -32.46 | -29.57 | -16.7 | -16.8 | 82.22 | -21.14 | Upgrade
|
| Free Cash Flow Per Share | -0.24 | -0.22 | -0.12 | -0.12 | 0.60 | -0.15 | Upgrade
|
| Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.300 | 0.500 | 0.500 | Upgrade
|
| Dividend Growth | 0% | 0% | -66.67% | -40.00% | 0% | -12.50% | Upgrade
|
| Gross Margin | 26.10% | 26.73% | 31.98% | 36.70% | 39.16% | 38.96% | Upgrade
|
| Operating Margin | -13.31% | -7.87% | 6.25% | 14.35% | 17.78% | 18.38% | Upgrade
|
| Profit Margin | -16.41% | -10.75% | 4.61% | 13.13% | 15.00% | 15.58% | Upgrade
|
| Free Cash Flow Margin | -5.93% | -4.93% | -2.33% | -2.16% | 10.29% | -2.77% | Upgrade
|
| EBITDA | -14.01 | 11.59 | 107.29 | 174.33 | 207.38 | 209 | Upgrade
|
| EBITDA Margin | -2.56% | 1.93% | 14.97% | 22.39% | 25.95% | 27.38% | Upgrade
|
| D&A For EBITDA | 58.82 | 58.79 | 62.51 | 62.57 | 65.29 | 68.68 | Upgrade
|
| EBIT | -72.83 | -47.2 | 44.78 | 111.76 | 142.09 | 140.32 | Upgrade
|
| EBIT Margin | -13.31% | -7.87% | 6.25% | 14.35% | 17.78% | 18.38% | Upgrade
|
| Effective Tax Rate | - | - | 34.33% | 12.35% | 20.81% | 25.23% | Upgrade
|
| Advertising Expenses | - | 3.82 | 3.81 | 5.92 | 20.65 | 21.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.